Event Specialty: Robotics
Auris Systems Team staff members Dr. David Noonan and Dr. Chauncey Graetzel will present at the Stanford Surgical Robotics Seminar on March 8. Their presentation on the Monarch Platform will be open to the public.
The seminar, titled “The Monarch Platform -- from concept to commercial reality,” covers the development of the Monarch Platform. Dr. Noonan and Dr. Graetzel will give attendees an overview of the Monarch Platform, the world’s first robotic endoscopic system for use in the lungs. They will discuss how the system provides Reach, Vision, and Precise Control to enable physicians to access parts of the lung that were previously unreachable with manual bronchoscopy methods.
The seminar will also examine some of the technical challenges that Auris had to overcome during the development process. Additionally, Dr. Noonan and Dr. Graetzel will share insights into what happens when a medical robotics startup like Auris goes commercial.
Dr. Noonan is the Director of Systems, Algorithms, and Robotics at Auris. He helped lead the development of the Monarch Platform. Prior to joining the Auris team, he worked on Image Guided Robotics and Fiber Optic RealShape (FORS) technology as a Research Scientist at Philips Research North America.
As Principal Systems Engineer at Auris, Dr. Graetzel led the development and commercial release of some of the key robotic algorithms controlling the platform. Prior to working at Auris, he helped bring novel robotic optical devices to market as Head of Research at Optotune.Learn more about the Stanford Surgical Robotics Seminar
Bronchoscopy Important Safety Statement:
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Urology Important Safety Statement:
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.